A Agilent Technologies Inc.

Agilent Releases 2019 Corporate Social Responsibility Report

Agilent Technologies Inc. (NYSE: A) today launched its 19th annual report, highlighting innovations and advancements achieved in 2019 and sharing the company’s response to the global pandemic in 2020.

“Agilent’s mission is to provide trusted answers and insights that advance the quality of life. We know that a focus on improving our environmental progress, our social commitments and good growth are essential to achieving this mission,” said Mike McMullen, president and CEO of Agilent. “Throughout 2019, and especially in 2020, we’ve been grateful for the opportunity to have a positive impact on people and communities around the globe.”

The report includes updates on the environmental, social and governance (ESG) strategies of Agilent and the Agilent Foundation. Some of the highlights of 2019 include:

Environment: Agilent strives to consistently improve sustainability in its operations as well as through its innovative products and technologies.

  • Increased its commitment to clean, reusable energy with the addition of three new solar sites that will provide a total carbon offset of 277 metric tons.
  • Diverted 85% of solid waste and 94% of total waste from landfills globally.
  • Reduced water (by headcount) by 19%.
  • Exceeded goal with 17% reduction of CO2e by sq. ft. and 30% reduction by headcount in 2019.
  • Eliminated the use of plastic foams in over 25% of packaging in the U.S.; for remaining packaging that required foam, implemented the use of material that contains 60%-100% recycled content.
  • Recognized as Barron’s no. 1 Most Sustainable Company for 2019.

Social: Agilent believes in making direct and indirect economic impacts around the world through its products and people.

  • Invested $7.5 million in philanthropic efforts and equipment:
    • $4,700,058 in global university grants and equipment, supporting science and technology research at the forefront of bioanalytic measurement technologies.
    • $2,412,466 in pre-university science-education grants and other community investment programs helping hundreds of thousands of students, educators and communities worldwide.
    • Through its employee matching gift programs, the Agilent Foundation provided an additional $391,920 in matching donations.

Governance: Agilent is passionate about achieving good growth — growth that benefits not only the bottom line but also employees, communities and the environment.

  • Recognized by numerous organizations for gender equity and diversity achievements, including by Forbes as one of America’s Best Employers for Diversity 2019 and one of America’s Best Employers for Women 2019.
  • In 2020, Agilent established new measures in the areas of employee perception, leadership gender diversity and pay equity.

Agilent’s 2019 Corporate Social Responsibility report is based on a combination of quantitative and qualitative data relating to its environmental and social performance during fiscal year 2019 (Nov. 1, 2018, to Oct. 31, 2019). Data is recorded on a companywide basis unless otherwise indicated. Agilent publishes its Corporate Social Responsibility Report annually and the 2019 Corporate Sustainability Report is prepared in accordance with GRI standards: core option.

To view the complete CSR report and learn more about Agilent’s impact, please see the report on the Agilent website.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions and people provide trusted answers to customers’ most challenging questions. The company generated revenue of $5.34 billion in fiscal 2020 and employs 16,400 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to the Agilent . Follow Agilent on , , and .

EN
11/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch